Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206

Benzinga Newsdesk www.benzinga.com Positive 71.6%

Neg 0% Neu 0% Pos 71.6%

Morgan Stanley analyst Judah Frommer maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $201 to $206.